Exploring a Synergistic Approach: Dual GLP-1 Agonist Combined with Degludec Basal Insulin for Early Type 1 Diabetes Treatment and its Impact on Albumin-Insulin Producing Cells Expression.
Amr AhmedMaher Monir AklPublished in: Advanced pharmaceutical bulletin (2024)
GLP-1 agonists show considerable potential in the management of type 1 diabetes by protecting residual beta cells, promoting cell proliferation, and reprogramming hepatic cells. The integration of modified GLP-1 agonists with albumin ligands could further enhance these effects. The manuscript underscores the need for continued research to fully explore this therapeutic approach. The proposed treatment strategy, which combines the autoimmune hypothesis, the proliferative effects of GLP-1, and albumin ligand modifications, aims to restore beta cell mass and function, thereby improving the quality of life for individuals with type 1 diabetes. Clinical trials are planned for 2024 under the registration ‹Amr Ahmed, Maher M. Akl, Semaglutide GLP1 Agonists with Degludec Basal-bolus Insulin in Early Type 1 Diabetes to Basalbolus› (ClinicalTrials.gov Identifier NCT06057077).
Keyphrases
- type diabetes
- induced apoptosis
- glycemic control
- cell cycle arrest
- clinical trial
- cell proliferation
- cardiovascular disease
- oxidative stress
- poor prognosis
- stem cells
- risk assessment
- metabolic syndrome
- adipose tissue
- bone marrow
- drug delivery
- climate change
- cell therapy
- mesenchymal stem cells
- antimicrobial resistance